Results from a 26-patient prospective multi-center study suggest that Moximed’s Atlas™ knee provided rapid, clinically-effective pain relief and an excellent safety profile in patients with early knee OA in the pre-arthroplasty disease stage.
Atlas obtained CE Mark approval in 4Q15. Early EU launch is underway. The system is described as a next-generation knee joint unloader for pre-arthroplasty patients, and builds on technology from the company’s KineSpring® implantable device designed to unload weight on osteoarthritic knee joints.
Results from a 26-patient prospective multi-center study suggest that Moximed's Atlas™ knee provided rapid, clinically-effective pain relief and an excellent safety profile in patients with early knee OA in the pre-arthroplasty disease stage.
Atlas obtained CE Mark approval in 4Q15. Early EU launch is underway. The system is described as a...
Results from a 26-patient prospective multi-center study suggest that Moximed’s Atlas™ knee provided rapid, clinically-effective pain relief and an excellent safety profile in patients with early knee OA in the pre-arthroplasty disease stage.
Atlas obtained CE Mark approval in 4Q15. Early EU launch is underway. The system is described as a next-generation knee joint unloader for pre-arthroplasty patients, and builds on technology from the company’s KineSpring® implantable device designed to unload weight on osteoarthritic knee joints.
Copy to clipboard 
